A Randomized, Double-blind, Placebo-controlled Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Refractory Chronic Cough

Next Previous
Trial Profile

A Randomized, Double-blind, Placebo-controlled Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Refractory Chronic Cough

Recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Mar 2018

At a glance

  • Drugs Serlopitant (Primary)
  • Indications Cough
  • Focus Therapeutic Use
  • Acronyms TUSSIX
  • Sponsors Menlo Therapeutics

    • Most Recent Events

    • 28 Mar 2018 According to the Menlo Therapeutics media release, data from this study is expected in the fourth quarter of 2018.
    • 16 Oct 2017 Status changed from not yet recruiting to recruiting.
    • 18 Sep 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top